These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10422782)

  • 21. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition.
    Huang J; Rebello SS; Faul JD; Lucchesi BR
    Pharmacology; 1999 May; 58(5):252-64. PubMed ID: 10087466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022.
    Shimazawa M; Takiguchi Y; Umemura K; Kondo K; Nakashima M
    Eur J Pharmacol; 1997 Jun; 328(2-3):183-9. PubMed ID: 9218700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of ME3277, a nonpeptide glycoprotein IIb/IIIa receptor antagonist, on the survival of skin flaps.
    Morioka D; Noda K; Satoh K; Hosaka Y
    Ann Plast Surg; 1998 Oct; 41(4):452-3. PubMed ID: 9788235
    [No Abstract]   [Full Text] [Related]  

  • 25. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
    Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
    Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist.
    Mousa SA; DeGrado WF; Mu DX; Kapil RP; Lucchesi BR; Reilly TM
    Circulation; 1996 Feb; 93(3):537-43. PubMed ID: 8565173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model.
    Imura Y; Kiyota Y; Nagai Y; Nishikawa K; Terashita Z
    Thromb Res; 1995 Jul; 79(1):95-107. PubMed ID: 7495108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitory effect of a novel orally active GP IIb/IIIa inhibitor, SC-54684A on intimal thickening in the guinea pig femoral artery.
    Umemura K; Nishiyama H; Kikuchi S; Kondo K; Nakashima M
    Thromb Haemost; 1996 Nov; 76(5):799-806. PubMed ID: 8950793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prohemorrhagic and bleeding time activities of recombinant tissue plasminogen activator, heparin, aspirin, and a glycoprotein IIb/IIIa antagonist.
    Mihara K; Aoki T; Moriguchi A; Maeda M; Furuichi Y; Matsuoka N; Mutoh S
    J Neurotrauma; 2005 Nov; 22(11):1362-73. PubMed ID: 16305324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig.
    Samama CM; Bonnin P; Bonneau M; Pignaud G; Mazoyer E; Bailliart O; Maffrand JP; Viars P; Caen JP; Drouet LO
    Thromb Haemost; 1992 Nov; 68(5):500-5. PubMed ID: 1455394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist.
    Hoffmann P; Bernat A; Savi P; Herbert JM
    J Pharmacol Exp Ther; 1998 Aug; 286(2):670-5. PubMed ID: 9694919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis.
    Makkar RR; Litvack F; Eigler NL; Nakamura M; Ivey PA; Forrester JS; Shah PK; Jordan RE; Kaul S
    Circulation; 1997 Feb; 95(4):1015-21. PubMed ID: 9054765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
    Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
    Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The novel thromboxane A2 receptor antagonist KW-3635 abolishes the cyclic flow reduction in the canine carotid artery.
    Higo K; Karasawa A
    Biol Pharm Bull; 1994 Jul; 17(7):902-6. PubMed ID: 8000373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis.
    Frederick LG; Suleymanov OD; King LW; Salyers AK; Nicholson NS; Feigen LP
    Circulation; 1996 Jan; 93(1):129-34. PubMed ID: 8616919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
    Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796.
    Hennan JK; Hong TT; Willens DE; Driscoll EM; Giboulot TA; Lucchesi BR
    Br J Pharmacol; 2002 Jul; 136(6):927-37. PubMed ID: 12110617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation.
    Choudhri TF; Hoh BL; Zerwes HG; Prestigiacomo CJ; Kim SC; Connolly ES; Kottirsch G; Pinsky DJ
    J Clin Invest; 1998 Oct; 102(7):1301-10. PubMed ID: 9769322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.